– USA, CA – Veracyte, Inc. (NASDAQ: VCYT), a global genomic diagnostics company, today announced the appointment of Muna Bhanji, R.Ph., a global senior healthcare executive, to its board of directors, effective immediately.
“We are thrilled to welcome Muna Bhanji to our board,” said Chairman and CEO, Bonnie Anderson. “She is a healthcare industry veteran with a distinguished career of driving successful commercialization and market access strategies across a range of products in global markets. Her guidance will be instrumental as we expand our global footprint with a growing menu of advanced genomic tests that improve care for patients at every step of their journey. This includes our planned international introduction later this year of the Envisia Genomic Classifier on the nCounter Analysis System to improve diagnosis of patients with suspected interstitial lung disease.”
About Muna Bhanji
Ms. Bhanji brings more than 30 years of strategic and operational experience in the biopharmaceutical industry with a proven track record of commercial leadership, growth and value creation. She built her career at Merck, serving most recently as SVO, Global Market Access & Policy, Global Human Health. In that role, she developed pharmaceutical access and affordability strategies in a highly regulated environment, working with key stakeholders to support access to medicines in the United States, Europe, Japan, China and the emerging regions of Latin America, Asia Pacific, the Middle East and Africa. Ms. Bhanji serves on the boards of biopharmaceutical companies Ardelyx, Inc. and Cytokinetics, Inc., as well as the nonprofit organization Corus International. She previously served on the board of Possible Health, a non-profit with ties to Nepal that delivers affordable and high-quality care to rural and underserved communities. Ms. Bhanji also served on the board of the Foundation of Managed Care Pharmacy, which is the research, educational, and philanthropic arm of the Academy of Managed Care Pharmacy.
Ms. Bhanji earned her Bachelor of Science in Pharmacy degree from Rutgers University and an M.B.A. from St. Joseph’s University.
About Veracyte
Veracyte is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of genomic tests leverage advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company’s tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer, and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping and renal cancer tests are in development. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide. Veracyte is based in South San Francisco, California.
For more information: https://www.veracyte.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
